<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Diabetes Mellitus MeG-CLS-004</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h1 id="diabetes-mellitus">Diabetes Mellitus</h1>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<h3 id="diabetes-mellitus-dm-is-a-metabolic-disorder-characterized-by-chronic-hyperglycemia.-it-predisposes-to-blindness-limb-amputation-and-is-a-major-risk-factor-for-cardiovascular-disease-and-death.-type-2-dm-is-the-most-common-type-with-many-patients-having-no-symptoms-and-diagnosed-incidentally.">Diabetes mellitus (DM) is a metabolic disorder characterized by chronic hyperglycemia. It predisposes to blindness, limb amputation and is a major risk factor for cardiovascular disease and death. Type 2 DM is the most common type with many patients having no symptoms and diagnosed incidentally.</h3>
<p>This guideline covers the diagnoses and treatment of diabetes mellitus.</p>
<h3 id="target-user">Target User</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Nurses</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
</ul>
<h3 id="target-area-of-use">Target area of use </h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Gate Clinic</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Outpatient Department</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ward</p>
</div></li>
</ul>
<h3 id="key-areas-of-focus-new-additions-changes">Key areas of focus / New additions / Changes </h3>
<p>DM is diagnosed if fasting blood glucose is ≥ 7.0 mmol/L or random blood glucose ≥ 11.1 mmol/L with typical symptoms. Patients with newly diagnosed DM or features suggestive of complications should be referred from the Gate Clinic to the OPD. Management of DM is aimed at blood glucose control and prevention of complications using pharmacologic and non-pharmacologic measures.</p>
<p>Patients with type 1 DM will require lifelong insulin therapy and should be referred to EFSTH. Patients with type 2 DM will typically receive metformin alone or in combination with other drugs.</p>
<p>Insulin therapy should be considered in the in-patient management of DM if blood glucose is persistently &gt; 10 mmol/l. This can be achieved by giving scheduled basal, premeal and correctional doses of insulin.</p>
<h3 id="limitations">Limitations </h3>
<h2 id="this-guideline-does-not-address-the-management-of-hyperglycaemic-emergencies.-these-are-addressed-in-meg-cls-021-diabetic-ketoacidosis-and-meg-cls-046-hyperglycaemic-hyperosmolar-state.">This guideline does not address the management of hyperglycaemic emergencies. These are addressed in MeG-CLS-021 Diabetic ketoacidosis and MeG-CLS-046 Hyperglycaemic hyperosmolar state.</h2>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<div data-custom-style="Default">
<p>Many patients have no symptoms and are diagnosed incidentally while being investigated or treated for some other medical condition.</p>
</div>
<div data-custom-style="Default">
<p>Symptoms of diabetes mellitus at presentation may include:</p>
</div>
<ul>
<li><div data-custom-style="Default">
<p>Classic symptoms</p>
</div>
<ul>
<li><div data-custom-style="Default">
<p>increased thirst</p>
</div></li>
<li><div data-custom-style="Default">
<p>increased volume and frequency of urination</p>
</div></li>
<li><div data-custom-style="Default">
<p>polyphagia</p>
</div></li>
</ul></li>
<li><div data-custom-style="Default">
<p>Recurrent Infections</p>
</div>
<ul>
<li><div data-custom-style="Default">
<p>recurrent boils and other skin infections</p>
</div></li>
<li><div data-custom-style="Default">
<p>recurrent genital infections (persistent whitish discharge with itch in women, inflammation of glans penis in men)</p>
</div></li>
</ul></li>
<li><div data-custom-style="Default">
<p>unexplained abdominal pain (mimicking a surgical/acute abdomen),</p>
</div></li>
<li><div data-custom-style="Default">
<p>weight loss (more common in Type 1 DM)</p>
</div></li>
<li><div data-custom-style="Default">
<p>marked weakness</p>
</div></li>
<li><div data-custom-style="Default">
<p>blurred vision</p>
</div></li>
<li><div data-custom-style="Default">
<p>abnormal sensation in the legs and feet: pain, burning, numbness (“feels like walking on mud when barefoot”)</p>
</div></li>
<li><div data-custom-style="Default">
<p>foetal macrosomia</p>
</div></li>
<li><div data-custom-style="Default">
<p>foetal deaths</p>
</div></li>
</ul>
<div data-custom-style="Default">
<p>Consider the possibility of diabetes in all adults of any age with a BMI &gt; 25 kg/m<sup>2</sup> plus one or more of the following:</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Hypertension &gt; 140/90 mmHg</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>First degree relative with Type 2 DM</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Polycystic ovarian syndrome</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Previous history of foetal macrosomia</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Cardiovascular disease</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Previous history of impaired glucose tolerance</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Physical inactivity</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Previous diagnosis of dyslipidaemia</p>
</div></li>
</ul>
<p>Consider a diagnosis of Type 1 DM if:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Younger than 35 years</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Slim physique</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Rapid onset of symptoms</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Severe symptoms at first presentation (including DKA)</p>
</div></li>
</ul>
<p>Apart from the symptoms listed earlier, complications include:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Autonomic neuropathy: Abnormal sweating, resting tachycardia, erectile dysfunction, postural hypotension, gastrointestinal symptoms such as early satiety, nocturnal diarrhea, constipation</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Motor: Painful proximal weakness (difficulty getting up from sitting position)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Sensory neuropathy: Bilateral distal lower limb pain,</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Vascular: leg fatigue, claudication, stroke, ischaemic heart disease.</p>
</div></li>
</ul>
<h2 id="management-in-gate-clinic">Management in Gate Clinic</h2>
<h3 id="investigations">Investigations</h3>
<div data-custom-style="Default">
<p>Diagnose diabetes mellitus if you find:</p>
</div>
<ol type="1">
<li><div data-custom-style="Default">
<p><em><strong>Fasting Blood Glucose</strong></em> of 7.0 mmol/L or higher</p>
</div></li>
</ol>
<div data-custom-style="Default">
<p><strong>OR</strong></p>
</div>
<ol start="2" type="1">
<li><div data-custom-style="Default">
<p>A <em><strong>random blood glucose</strong></em> of 11.1 mmol/L or higher <strong>plus</strong> the classic symptoms of diabetes mellitus.</p>
</div></li>
</ol>
<div data-custom-style="Default">
<p>If patient is asymptomatic with abnormal fasting glucose, repeat the test for confirmation.</p>
</div>
<div data-custom-style="Default">
<p><em><strong>Dipstick urinalysis:</strong></em> This may show glycosuria. Proteinuria or ketonuria may also be present.</p>
</div>
<h3 id="alarm-features">Alarm features</h3>
<p>If a patient with high blood glucose has one or more of the following signs or symptoms, the doctor should be called to see them immediately.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Drowsiness</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Fever &gt; 38ºC</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Severe Weakness</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Confusion</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Signs of dehydration</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Deep sighing breathing</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Abdominal pain</p>
</div></li>
</ul>
<h3 id="when-to-refer-to-the-doctor-in-opd">When to refer to the doctor in OPD</h3>
<p>Also refer patients to the doctor who have:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Newly diagnosed diabetes mellitus</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>You are unsure of the diagnosis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Proteinuria or ketonuria is discovered alongside high blood glucose</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Glycosuria of ++ or more</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Patient looks very ill and weak alongside a high blood glucose</p>
</div></li>
</ul>
<h3 id="management-of-patients-with-a-high-blood-glucose">Management of patients with a high blood glucose </h3>
<div data-custom-style="Default">
<p><em><strong>Patient Education:</strong></em></p>
</div>
<div data-custom-style="Default">
<p>Structured education to all patients and carers about diabetes mellitus (cause, course and prognosis), diabetes self-management, nutrition and lifestyle modification. This includes diet, exercise and weight management (loss of 5-10% of body weight initially).</p>
</div>
<h2 id="management-in-opd">Management in OPD</h2>
<h3 id="routine-examination">Routine examination</h3>
<p>Review BMI at each visit.</p>
<p>Check for postural hypotension at baseline, annually and if symptomatic.</p>
<p>Foot exam:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Inspect both feet at each visit for calluses, dystrophic nails, joint deformities, tinea pedis, ulcers.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Check for reduced peripheral pulsation in feet at baseline, annually and if symptomatic.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Baseline and annual neurologic examination of feet (10 g monofilament and 128 Hz tuning fork vibration test).</p>
</div></li>
</ul>
<p>Fundoscopy for retinal changes.</p>
<h3 id="routine-investigation">Routine investigation</h3>
<p><em>Fasting Blood Glucose</em> at each follow up visit</p>
<p>Baseline and annual <em>serum electrolytes, urea and creatinine</em>: calculate estimated glomerular filtration rate (eGFR) at <span data-custom-style="Hyperlink"><a href="https://www.kidney.org/professionals/kdoqi/gfr_calculator">https://www.kidney.org/professionals/kdoqi/gfr_calculator</a></span></p>
<p>Calculate cardiovascular risk at <span data-custom-style="Hyperlink"><a href="https://qrisk.org/2017/">https://qrisk.org/2017/</a></span> - check lipid profile if the risk is borderline (5-10% in the next 10 years).</p>
<p><em>Urinalysis</em>: Glycosuria and ketonuria may be present. Proteinuria (++) or haematuria (with red cell casts) may indicate nephropathy.</p>
<p>Baseline <em>ECG</em></p>
<p>For staff and those who can afford private fees: baseline <em>HbA1c assay</em>, recheck 6-monthly (if at target) or 3-monthly (not at target)</p>
<h3 id="treatment">Treatment</h3>
<p>The goals of treatment are:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Glucose control;</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Cardiovascular risk reduction;</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Prevention and management of complications.</p>
</div></li>
</ul>
<p><em>Lifestyle measures</em>: Diet, smoking cessation, moderation in alcohol intake, adequate physical activity and weight management.</p>
<p><em>Pharmacologic Therapy:</em></p>
<p><em>Glucose control:</em> Target blood glucose levels are 4.4 – 7.2 mmol/l (fasting and pre-meal), less than 10.0 mmol/l post-prandial. Target HbA1c is less than 7%. Individualize higher targets for older patients or those prone to hypoglycaemia. (target up to 8.5% HbA1c and up to 10.0 mmol/l pre-meal blood glucose)</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Type 1 patients: usually insulin dependent from diagnosis. Usually maintained on combinations of regular insulin and intermediate acting insulin e.g. Mixtard (70/30). Refer to EFSTH</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Initial drug of choice in Type 2 is metformin unless contraindicated. Start at 500 mg orally once daily. Increase to 500 mg twice daily the next week and then 500 mg three times daily the week after. The usual maximum dose is 1000 mg twice daily.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>For patients with baseline FBS &gt; 16 mmol/l, baseline HbA1c ≥ 9% or FBS not at target after 3 months, commence gliclazide along with metformin.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Assess medication adherence at each visit.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>If still not at target despite maximal doses of gliclazide and metformin, consider adding another oral agent or insulin. Patients other than staff will need to be referred to EFSTH diabetic clinic at this point.</p>
</div></li>
</ul>
<p><em>Hypoglycaemia:</em> Treat at blood glucose less than 4 mmol/l or presence of typical symptoms.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Unlikely to occur if patient is on metformin monotherapy.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Educate patient on prevention, symptoms and immediate care needed. Patients on sulfonylureas or insulin should carry three candies (sweets) or sugar cubes always to treat hypoglycaemia.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>If hypoglycaemia occurs, assess diet, dose and physical activity with patient and agree on dose adjustment.</p>
</div></li>
</ul>
<p><em>Blood pressure control:</em> Target BP is &lt; 140/90 mmHg</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>If BP is &lt; 160 mmHg systolic and &lt; 100 mmHg diastolic, start with a single drug preferably a Calcium Channel Blocker (use an ACE Inhibitor instead if proteinuria or chronic kidney disease is present)</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>If BP is ≥ 160 mmHg systolic or 100 mmHg diastolic, start with two drugs preferably Calcium Channel Blocker + ACE Inhibitor</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Avoid beta blockers as they can mask hypoglycaemia symptoms</p>
</div></li>
</ul>
<p><em>Cholesterol:</em> Statin therapy with atorvastatin if patients is over 40 years or has a history of atherosclerotic cardiovascular disease. Higher doses are needed for patients with cardiovascular disease.</p>
<p><em>Antiplatelet therapy:</em> consider if 10 year cardiovascular risk is &gt; 10% – Soluble aspirin 75 mg daily or clopidogrel 75 mg daily.</p>
<p>Encourage patients to seek annual comprehensive eye examination at SZREC.</p>
<p>For distal sensory polyneuropathy, carbamazepine or amitriptyline may provide improvement in discomfort over time. Metformin may cause Vitamin B12 deficiency which may contribute to neuropathy. This may be detected as a raised MCV and can be treated with 1 ml Vitamin B12 im monthly.</p>
<p><em>Nephropathy:</em> Monitor serum electrolytes, urea and creatinine if proteinuria is present (or on ACE inhibitor). Discuss referral to EFSTH if eGFR is &lt; 60 mL/min/1.73 m<sup>2</sup>.</p>
<h3 id="pregnancy-and-dm">Pregnancy and DM</h3>
<div data-custom-style="Default">
<p><em>Pre-existing Type 2 DM:</em> Tight glucose control is important. If this can be achieved on Metformin alone then this can continue. The patient will need specialist obstetric care and many will need insulin treatment.</p>
</div>
<div data-custom-style="Default">
<p><em>Gestational Diabetes:</em></p>
</div>
<ul>
<li><div data-custom-style="Default">
<p>Lifestyle changes may be adequate for control</p>
</div></li>
<li><div data-custom-style="Default">
<p>Metformin is the first line therapy</p>
</div></li>
<li><div data-custom-style="Default">
<p>Insulin therapy may be needed.</p>
</div></li>
<li><div data-custom-style="Default">
<p>Refer for specialist obstetric care</p>
</div></li>
</ul>
<h2 id="management-on-the-ward">Management on the Ward</h2>
<p>All adult patients (including those not previously diagnosed diabetic) admitted to the ward should have baseline blood glucose checked.</p>
<p>Blood glucose &gt; 7.8 mmol/l in an in-patient is considered as hyperglycaemia. If blood glucose is persistently &gt; 10 mmol/l, consider starting insulin therapy with a target blood glucose of 7.8 – 10.0 mmol/l. Calculate total daily dose (TDD) in units of insulin required.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>For patients recovering from DKA, TDD may safely be set at two-thirds (2/3) of their previous total daily requirement of IV soluble insulin.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>For patients previously on insulin at home, use previous total daily dose if they were at glucose targets.</p>
</div>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Otherwise, calculate TDD by multiplying body weight in kg by the factor N from the Table 1 below</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Adjust TDD downward if nutritional intake is less than normal for patient.</p>
</div></li>
</ul></li>
</ul>
<p><em>Table 1. Factor for calculating Total Daily Dose of Insulin based on weight:</em></p>
<table>
<thead>
<tr class="header">
<th><strong>If patient has these features...</strong></th>
<th><strong>N =</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Underweight, elderly, CKD or severe liver disease</td>
<td>0.3</td>
</tr>
<tr class="even">
<td>Normal-weight patients, including Type 1 diabetes.</td>
<td>0.4</td>
</tr>
<tr class="odd">
<td>Overweight</td>
<td>0.5</td>
</tr>
<tr class="even">
<td>Obese, high-dose steroids, or other markers of significant insulin resistance.</td>
<td>0.6</td>
</tr>
</tbody>
</table>
<p>For patients who are able to eat or who are given tube feeding boluses, give half the calculated TDD as a <em>basal</em> subcutaneous insulin isophane (Insulatard) either as a single dose or as two divided doses 12 hourly. Give the other half as pre-<em>meal</em> subcutaneous soluble Insulin (Actrapid) 30 minutes before meals with the dose divided equally between the meals.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>If pre-meal blood glucose is &lt; 3.9 mmol./l, treat for hypoglycaemia and reduce pre-meal doses of regular insulin by half.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>If pre-meal blood glucose is &gt;10 mmol/l, add <em>correctional</em> insulin dose to pre-meal dose of regular insulin using the Table 2 below.</p>
</div></li>
</ul>
<div data-custom-style="Default">
<p><em>Table 2. Correctional doses of insulin based on pre-meal or 6-hourly blood glucose</em></p>
</div>
<table>
<thead>
<tr class="header">
<th><em>Blood Glucose (mmol/l)</em></th>
<th><em>If TDD &lt;40 units/day, add:</em></th>
<th><em>If TDD is 40-80 units/day, add:</em></th>
<th><em>If TDD &gt;80 units/day, add:</em></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>&lt; 3.9</strong></td>
<td><strong>Reduce dose by half &amp; call doctor</strong></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td>4 – 10</td>
<td>0 unit</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td>10.1 - 11.0</td>
<td>1 unit</td>
<td>2 units</td>
<td>4 units</td>
</tr>
<tr class="even">
<td>11.1 - 12.5</td>
<td>2 units</td>
<td>4 units</td>
<td>6 units</td>
</tr>
<tr class="odd">
<td>12.6 - 14.0</td>
<td>3 units</td>
<td>6 units</td>
<td>8 units</td>
</tr>
<tr class="even">
<td>14.1 - 16.5</td>
<td>4 units</td>
<td>8 units</td>
<td>10 units</td>
</tr>
<tr class="odd">
<td>16.6 - 19.9</td>
<td>5 units</td>
<td>10 units</td>
<td>12 units</td>
</tr>
<tr class="even">
<td><strong>20 and above</strong></td>
<td><strong>6 units</strong></td>
<td><strong>12 units</strong></td>
<td><strong>14 units</strong></td>
</tr>
<tr class="odd">
<td></td>
<td><strong>Call doctor after giving insulin</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
<p>For patients on nil per oral (NPO) or receiving only clear fluids, give only half (50%) of the calculated TDD as <em>basal</em> isophane insulin either as a single subcutaneous doses or as two divided doses every 12 hours. These patients should also receive 5% dextrose infusion at 500 mls 4 – 6 hourly.</p>
<p>Check blood glucose 6 hourly. Give <em>correctional</em> dose of insulin if needed</p>
<p>Reassess and modify insulin therapy daily based on trends of blood glucose.</p>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care</h2>
<h2 id="before-administering-insulin">Before administering insulin:</h2>
<ul>
<li><h2 id="always-check-blood-glucose">Always check blood glucose</h2></li>
<li><div data-custom-style="List Paragraph">
<p>Confirm type of insulin to be given and route</p>
</div></li>
<li><h2 id="confirm-insulin-concentration-should-be-100-uml">Confirm insulin concentration (should be 100 U/ml)</h2></li>
<li><h2 id="confirm-insulin-syringe-units-should-be-100-uml">Confirm insulin syringe units (should be 100 U/ml)</h2></li>
<li><h2 id="confirm-dosage-before-administration">Confirm dosage before administration</h2></li>
</ul>
<h2 id="in-addition-for-pre-meal-insulin">In addition, for pre-meal insulin:</h2>
<ul>
<li><h2 id="confirm-availability-of-food">Confirm availability of food</h2></li>
<li><h2 id="confirm-ability-and-willingness-of-patient-to-eat.">Confirm ability and willingness of patient to eat.</h2></li>
</ul>
<p>Insulin protocols for each patient should be updated daily and available at the bedside.</p>
<h2 id="references">References:</h2>
<h2 id="maynard-g-wesorick-dh-omalley-c-inzucchi-se-on-behalf-of-society-of-hospital-medicine-glycemic-control-task-force.-subcutaneous-insulin-order-sets-and-protocols-effective-design-and-implementation-strategies.-j-hosp-med.-2008-sep35-suppl29-41.-doi-10.1002jhm.354.">Maynard G, Wesorick DH, O&#39;Malley C, Inzucchi SE on behalf of Society of Hospital Medicine Glycemic Control Task Force. Subcutaneous insulin order sets and protocols: effective design and implementation strategies. J Hosp Med. 2008 Sep;3(5 Suppl):29-41. doi: 10.1002/jhm.354.</h2>
<h2 id="langan-rc-goodbred-aj.-vitamin-b12-deficiency-recognition-and-management.-am-fam-physician.-2017-sep-15966384-389">Langan RC, Goodbred AJ. Vitamin B12 Deficiency: Recognition and Management. Am Fam Physician. 2017 Sep 15;96(6):384-389</h2>
<h2 id="american-diabetes-association.-standards-of-medical-care-in-diabetes2018.-diabetes-care-201841suppl.-1">American Diabetes Association. Standards of Medical Care in Diabetes—2018. Diabetes Care 2018;41(Suppl. 1)</h2>
<p>Type 2 diabetes mellitus in adults. BMJ Best Practice. November 2017. Accessed 26th June 2018. Available at bestpractice.bmj.com</p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Name: Fatai Akemokwe</th>
<th>Date: 30 June 2018</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Name: Karen Forrest</td>
<td>Date: 24 July 2018</td>
</tr>
<tr class="even">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td></td>
</tr>
<tr class="even">
<td>2.0</td>
<td>Expanded to include management in areas outside gate clinic</td>
<td>31 July 2020</td>
</tr>
<tr class="odd">
<td>2.1</td>
<td>Executive summary added</td>
<td>31 July 2020</td>
</tr>
<tr class="even">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
